Amgen Publishes Presentation on Imdelltra Survival Benefit in Small Cell Lung Cancer

• Amgen published its ESMO 2026 update presentation, highlighting Phase 3 DeLLphi-305 results for Imdelltra combined with Imfinzi.
• First-line maintenance treatment in extensive-stage small cell lung cancer yielded median overall survival of 21.1 months versus 12.7 months with Imfinzi alone.
• The combination reduced the risk of death by 58%, with a hazard ratio of 0.42; P < 0.001.
• Median progression-free survival reached 7.4 months versus 1.9 months; the hazard ratio was 0.34.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.